OFD 2024 Bilingual (English / French)
Session Detail
Presentation Summary
Drug-drug interactions (DDIs) in oncology can include pharmacokinetic (PK) and pharmacodynamic (PD) interactions with oral anti-cancer, chemotherapy, and monoclonal antibodies which require assessment and management by oncology pharmacists to optimize care for patients with cancer. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies which improve T-lymphocyte directed cytotoxicity against malignant cancer cells and have been incorporated into many treatment guidelines for hematologic and solid tumour malignancies. ICIs are not associated with traditional PK DDIs with absorption, distribution, metabolism, transport or elimination, however, various PD interactions have been identified with prospective and retrospective, observational research. Oncology pharmacists should be aware of PD DDIs identified with ICIs as retrospective evidence correlates these interactions with poorer clinical outcomes in select patient populations. This presentation will aim to improve awareness of PD DDIs with ICIs identified in the literature, and provide practical strategies for pharmacists to discuss these DDIs with patients in an effort to optimize their cancer care.
Learning Objectives:
1. Recall clinically relevant pharmacodynamic (PD) drug-drug interactions (DDIs) with immune checkpoint inhibitors (ICIs) published in the literature.
2. Review literature for published PD ICI DDIs and assess implications with cancer related outcomes in applicable populations.
3. Implement practical assessment and management strategies for managing PD DDIs with ICIs.